A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

• Mathematical modeling of JAK2V617F clonal expansion in a general population cohort

  2026 Proceedings of the National Academy of Sciences article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  0

  citations
• Type-I interferon–activated NK cells control polycythemia vera in vivo

  2026 Blood article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment

  1

  citations
• The V617F mutation in JAK2 renders myeloid cells more sensitive to IL-6-mediated gp130 signaling

  2025 bioRxiv (Cold Spring Harbor Laboratory) preprint Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  0

  citations
• Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study

  2025 Therapeutic Advances in Hematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  1

  citations
• Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alfa

  2025 Blood Advances article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  2

  citations
• Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry

  2024 Cell Communication and Signaling article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  18

  citations
• Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche

  2024 Stem Cell Reports article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  18

  citations
• Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alpha

  2023 Research Square preprint Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  2

  citations
• The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

  2023 Frontiers in Oncology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  15

  citations
• Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial

  2023 Annals of Hematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  13

  citations
• Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis

  2023 Frontiers in Oncology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  5

  citations
• Essenzielle Thrombozythämie und Polycythaemia vera

  2023 Die Onkologie article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment

  2

  citations
• Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

  2022 Annals of Hematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  11

  citations
• Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

  2021 Leukemia article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  79

  citations
• Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN

  2020 Blood article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

  109

  citations

15 results